<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625481</url>
  </required_header>
  <id_info>
    <org_study_id>WP2-072-02</org_study_id>
    <nct_id>NCT01625481</nct_id>
  </id_info>
  <brief_title>Seal-V Safety and Performance Study</brief_title>
  <official_title>Prospective, Single Arm, Open Label, Non-randomized Study to Evaluate The Safety and Performance of The Seal-V System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sealantis Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sealantis Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further assess the safety and performance of Seal-V as an&#xD;
      adjunct to standard surgical procedure for achieving hemostasis in patients undergoing&#xD;
      peripheral vascular reconstruction surgeries using synthetic grafts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTH, Time to Hemostasis</measure>
    <time_frame>Perioperative; within 10 minutes after clamp release</time_frame>
    <description>Duration from the point at which circulation is restored to the graft/artery until bleeding ceases at the treatment site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful cessation of bleeding at a treatment site</measure>
    <time_frame>Perioperative; within 10 minutes after clamp release</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>Perioperative</time_frame>
    <description>Measured by weighing the surgical swabs used only in the application area and used from the time Seal-V was applied until hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of successful deployment of the Seal-V device</measure>
    <time_frame>Perioperative</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>C.Surgical Procedure; Vascular (Peripheral)</condition>
  <arm_group>
    <arm_group_label>Seal-V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seal-V</intervention_name>
    <description>Seal-V is applied adjunctively to cover the suture lines.</description>
    <arm_group_label>Seal-V</arm_group_label>
    <other_name>SEAlantis Vascular WP2(A)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of &gt;18 years of age&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Patients requiring vascular reconstruction surgeries using synthetic (such as PTFE,&#xD;
             Dacron) or autologous (such as native veins) grafts, including the following:&#xD;
&#xD;
          -  Peripheral bypass surgeries, such as arterio-arterial bypasses [including:&#xD;
             axillo-(bi)femoral, ilio-(bi)femoral, femoro-femoral, ilio-popliteal, femoro-popliteal&#xD;
             (including below knee), femoro-tibial vessel bypass]&#xD;
&#xD;
          -  Arteriovenous (AV) dialysis access shunt in the upper or lower extremity&#xD;
&#xD;
          -  Patients able and willing to complete all follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vascular surgery other than peripheral bypass surgeries and arteriovenous (AV)&#xD;
             dialysis access shunt procedures as described above&#xD;
&#xD;
          -  Reoperation at the same treatment site&#xD;
&#xD;
          -  Known sensitivity to device materials, such as indigo carmine dye or alginate&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Systemic infection&#xD;
&#xD;
          -  Participation in another clinical trial or treatment with any investigational agent in&#xD;
             past 30 days&#xD;
&#xD;
          -  Congenital coagulation disorders (e.g., thrombocytopenia [&lt;100,000 platelet count],&#xD;
             thromboasthenia, hemophilia, or von Willebrand disease)&#xD;
&#xD;
          -  Severe congenital or acquired immunodeficiency (e.g., HIV infection or long term&#xD;
             treatment with immunosuppressive drugs)&#xD;
&#xD;
          -  Prior radiation therapy to the operating field&#xD;
&#xD;
        Intraoperative Exclusion Criteria:&#xD;
&#xD;
          -  Major intraoperative complications that require resuscitation or deviation from the&#xD;
             planned surgical procedure&#xD;
&#xD;
          -  Intraoperative change in planned surgical procedure that results in the patient no&#xD;
             longer meeting preoperative inclusion and/or exclusion criteria&#xD;
&#xD;
          -  Local infection at the operating field&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rina Lev, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sealantis Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Vascular Surgery, Bnai-Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Surgery Department, Rambam Health Care</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery, Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>May 26, 2014</last_update_submitted>
  <last_update_submitted_qc>May 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

